Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 75

  • 960 clinical trials
  • 390 recruiting
  • 346 conditions
  • 28 countries

Conditions in this area

346 conditions with trials, the busiest first

Breast cancer170Prostate cancer102Ovarian cancer90Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer42Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer19Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+322

Clinical trials in Reproductive system and breast disorders

960 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

960 clinical trials

Prostate cancer metastatic+1

Not recruiting

Study of Pembrolizumab, Carboplatin, and Cabazitaxel for Patients with Aggressive Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel
  • Sponsor:Fundacion Oncosur

Infertility female+1

Not recruiting

Study on Ovarian Response in Women with Infertility Using Follitropin Delta and Menotrophin During Assisted Reproductive Technology

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Follitropin Delta
  • Sponsor:Ferring Pharmaceuticals A/S

Breast cancer metastatic+1

Not recruiting

Study on Imaging with 89Zr-Atezolizumab to Monitor Immune Responses in Patients with Metastatic Triple Negative Breast Cancer Using Atezolizumab and Drug Combination

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Karolinska University Hospital

Hormone-refractory prostate cancer

Not recruiting

Study Comparing [177Lu]LU-PSMA-I&T and Hormone Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Curium Pet France

Hormone-refractory prostate cancer+1

Not recruiting

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Infertility+2

Not recruiting

Study on Progesterone for Improving Birth Rates in Couples with Unexplained Infertility Undergoing Mild Ovarian Stimulation and Intrauterine Insemination

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Progesterone, Micronised
  • Sponsor:Universitair Medisch Centrum Utrecht

Perineal injury

Not recruiting

Study on Amoxicillin and Clavulanic Acid to Prevent Infection in Women with Obstetric Perineal Tear

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Amoxicillin
  • Sponsor:Region Hovedstaden

Breast cancer metastatic

Not recruiting

Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Triple negative breast cancer

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Triple negative breast cancer

Not recruiting

Study on the Safety and Effectiveness of Sacituzumab Govitecan for Patients with Triple Negative Metastatic Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Unicancer

Prostate cancer

Not recruiting

Study on the Effect of Degarelix and Ultrasound Therapy for Patients with Intermediate-Risk Prostate Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:Turku University Hospital

Prostate cancer

Not recruiting

Study on Surgery with or without Darolutamide for Patients with High-Risk or Locally Advanced Prostate Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Oncopole Claudius Regaud

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab76 clinical trialsLetrozole74 clinical trialsFulvestrant59 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane47 clinical trialsAnastrozole45 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.